[D-Trp6]-LH-RH

Names

[ Name ]:
[D-Trp6]-LH-RH

[Synonym ]:
5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycinamide
triptorelinum
triptorelinum [INN_la]
Glycinamide, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolyl-
triptoreline
TRIPORELIN
MFCD00167541
triptorelina
TRIPTORELIN AMIDE
UNII:9081Y98W2V
Triptorelin
TRIPTORELIN PAMOATE
Decapeptyl

Biological Activity

[Description]:

Triptorelin is a GnRH agaonist shown to inhibit estradiol-induced cancer cell proliferationIn vivo: (1) Triptorelin can improve the pregnancy rate by 12% to 15% in ewes6 and downregulate ovarian GnRHR-I expression of female rats, especially in late-growing follicles.(2) Triptorelin immunity blocked EET and UWT, inhibited uterine growth and development and enhance the expression levels s of ESR1, LHR, and FSHR proteins.

[Related Catalog]:

Signaling Pathways >> GPCR/G Protein >> GNRH Receptor

Research Areas >> Cancer

Peptides

[References]

[1]. Wei S et al. Triptorelin and cetrorelix induce immune responses and affect uterine development and expressions of genes and proteins of ESR1, LHR, and FSHR of mice. Immunopharmacol Immunotoxicol. 2016 Jun;38(3):197-204.

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.5±0.1 g/cm3

[ Molecular Formula ]:
C₆₄H₈₂N₁₈O₁₃

[ Molecular Weight ]:
1311.449

[ Exact Mass ]:
1310.630859

[ PSA ]:
487.92000

[ LogP ]:
-0.41

[ Index of Refraction ]:
1.723

[ Storage condition ]:
−20°C

Safety Information

[ Symbol ]:

GHS08

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H360

[ Precautionary Statements ]:
P201-P308 + P313

[ Personal Protective Equipment ]:
Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges

[ Hazard Codes ]:
T: Toxic;

[ Risk Phrases ]:
R60

[ Safety Phrases ]:
53-22-36/37/39-45

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
3

Articles

Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies.

Arch. Gynecol. Obstet. 287(3) , 447-53, (2013)

To evaluate the changes in the volume of rectovaginal endometriotic nodules infiltrating the rectum during 12-month treatment with hormonal therapies.This prospective, non-randomized, self-controlled ...

Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.

J. Clin. Oncol. 31(7) , 903-9, (2013)

To assess the efficacy of gonadotropin-releasing hormone agonist (GnRHa) in preventing chemotherapy-induced ovarian failure in patients treated for Hodgkin or non-Hodgkin lymphoma within the setting o...

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

N. Engl. J. Med. 371(2) , 107-18, (2014)

Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor-positive breast cancer.In two phase 3 trials, we randomly assi...